Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms

Published:2009-11 Issue:4 Volume:147 Page:495-506
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Grimwade Lizz F.,Happerfield Lisa,Tristram Colin,McIntosh Gary,Rees Mark,Bench Anthony J.,Boyd Elaine M.,Hall Marie,Quinn Amy,Piggott Nigel,Scorer Paul,Scott Mike A.,Erber Wendy N.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07870.x/fullpdf

Reference49 articles.

1. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation;Aboudola;American Journal of Surgical Pathology,2007

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort;Beer;Blood,2008

4. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis;Bogani;Haematologica,2007

5. A simple diagnostic test for MPL exon 10 mutations in myeloproliferative neoplasms;Boyd;British Journal of Haematology,2009

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance of low level JAK2 V617F in peripheral blood testing;Pathology;2024-08

2. Regulation of STAT5 phosphorylation and interaction with SHP1 by lnc-AC004893, a long non-coding RNA overexpressed in myeloproliferative neoplasms;Hematology;2024-07-16

3. MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures;2024-04-19

4. Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms;Nature Communications;2024-04-06

5. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results;Blood Advances;2024-03-18